Written by Aries Yuangga

Summary

Salesforce (NYSE: CRM) is going through a messy, but rational repricing as it transitions from “grow-at-all-costs SaaS” to a cash-flow & margin compounder:

• Stock has underperformed Nasdaq since mid-2025 after:
  • Soft cash-flow print in Q1,
  • Slightly weaker GAAP margin guidance for FY26,
  • And the surprise Informatica (INFA) acquisition.
• Despite that, underlying fundamentals are quietly improving:
  • Industry-leading gross margins continue to rise.
  • Scale benefits + falling fixed-cost ratio set up GAAP margin expansion.
  • Stock-based compensation already down to ~8% of revenue and trending lower.
• Market is effectively pricing CRM as if GAAP margins never improve from here.
  • Forward P/E ~20–21× with ~9% revenue growth and big margin runway = cheap vs peers.
• Informatica deal will depress GAAP EPS near term (amortization + restructuring), but should:
  • Increase scale,
  • Allow SBC optimization,
  • And broaden data + AI stack around Agentforce.

Thesis: This is not a momentum name anymore. It’s a patient value + quality SaaS play where GAAP earnings can grow faster than revenue as adjustments fade and scale kicks in.

Rating: BUY (Patient Accumulator), use the sell-off to build a long-term position over 12–24 months.

Technical Analysis

Current Price: ~US$227.88

Key Levels

Resistance

• US$276.21 → major horizontal resistance / prior range top
• US$296.55 → next big resistance zone; retest here lines up with a full sentiment reset

Accumulation Buy Zone

From your chart:

• US$218.01 → top of demand zone
• US$212.00 → bottom of accumulation zone

This band lines up with:

• Prior reaction lows,
• Fresh panic-sell candles,
• Area where risk–reward skews heavily in favor of long-term buyers.

Invalidation

• Weekly close < US$210 → suggests breakdown from current structure; wait for a deeper base before adding size.

Read

CRM is in a controlled de-rating leg after the Informatica announcement and softer FY26 GAAP guide.

Technically, a flush into 218–212 would complete a classic “capitulation into support” setup before any multi-month mean-reversion toward 270–295.

As long as price holds the accumulation band on a weekly closing basis, the long-term bullish structure (margin expansion story) remains intact.

Trading Setup

DCA Plan (Long-Term Investor Focus)

• 35% size: US$228–222 (current zone, early entry)
• 40% size: US$222–218 (primary accumulation zone)
• 25% size: US$218–212 (aggressive bids at bottom of demand zone)

→ Full-fill cost basis ≈ US$220–223 in a full flush scenario.

Risk Management

For Swing / Leveraged Traders

• Reduce or exit if:
  • Daily close < US$212, or
  • Weekly close < US$210 (structural break of support & rising risk of value-trap behavior)

For Long-Term Investors (3–5y Horizon)

Use a fundamental stop rather than pure price:

Thesis is in trouble only if:

• GAAP operating margins stop improving over multiple years,
• SBC creeps back up instead of trending down,
• Informatica integration clearly destroys value (no synergy, no scale, no cross-sell),
• Or CRM reverts to serial dilutive M&A with no discipline.

Take Profit Levels

• TP1: US$270–276 → lock 20–30% once the stock mean-reverts to major resistance.
• TP2: US$295–300 → big prior supply zone; natural place to resize down further.
• Stretch Target: US$320+ → achievable if GAAP EPS growth re-accelerates and market re-rates to a higher multiple.

Options / Income Ideas (Optional)

• Sell cash-secured puts at US$220 / 215 (30–45 DTE) → get paid to wait for entry closer to buy zone.
• If assigned, sell covered calls at US$290–310 to monetize volatility while holding core shares.

Why The Thesis Works (Pillars)

1️⃣ Margin Expansion Optionality Is Mispriced

• CRM enjoys top-tier gross margins in large-cap software.
• Operating margin still trails MSFT / ORCL due to:
  • Heavy past M&A,
  • Higher SBC,
  • Large opex footprint.

As scale continues and cost discipline remains, GAAP margins can move up a lot even on single-digit revenue growth, making EPS outgrow sales.

2️⃣ SBC & Adjustments Are Coming Down

• SBC now ~8% of sales and trending lower.
• As non-GAAP → GAAP gap closes over time:
  • Reported GAAP earnings will accelerate,
  • Quality of earnings improves,
  • Market is willing to pay a better multiple.

This is exactly the playbook for mature SaaS names moving from “growth stock” to “compounding cash-flow machine.”

3️⃣ Informatica Deal: Messy Optics, Long-Term Scale

Short term:

• Higher amortization,
• Restructuring costs,
• Integration risk.

Long term:

• Broader data + integration + AI stack around Salesforce core cloud,
• More cross-sell into CRM’s huge installed base,
• Ability to rationalize SBC & costs across both orgs.

The market sees only the near-term EPS drag; patient investors can underwrite the post-integration margin uplift.

4️⃣ Valuation vs Peers Is Attractive

At ~20–21× forward GAAP EPS with ~8–9% revenue growth, CRM trades:

• Roughly in line with peers on headline multiple,
• But with higher gross margin and larger margin runway than MSFT/ORCL’s mature software businesses.

If margins expand as expected, EPS CAGR can exceed peers even if the top line grows slower → that’s the mispriced angle.

5️⃣ Cash Flow Engine Still Intact

Despite a weak Q1 cash-flow print:

• Full-year cash-flow growth guidance was raised (from ~10.5% to ~12.5%).
• Management stepped up share buybacks in FY26 to support shareholders during volatility.

Free cash flow remains the anchor of the thesis; the Q1 disappointment looks more like a timing issue than structural damage.

Valuation & Scenarios (High Level)

Base Case (3–5 Years)

• Revenue CAGR ~8–9%,
• GAAP operating margin improves steadily as SBC & amortization drag ease,
• EPS CAGR mid-teens.

Fair multiple: 22–24× EPS.

→ Price range US$280–300 = solid high-teens annualized return from current levels.

Bull Case

• Informatica integration works smoothly,
• Agentforce & data platform drive incremental growth,
• GAAP margin ramps faster than expected.

EPS CAGR high-teens to 20%+; market re-rates to 25–27×.→ Price potential US$320–340+ over 3–5 years.

Bear Case

• Integration is messy; restructuring costs linger,
• Revenue growth drifts to low-single-digits,
• Margin expansion stalls; CRM stuck in “ex-growth SaaS” bucket.

Multiple compresses to 16–18×. → US$190–205 downside zone; still partially cushioned by cash flow & buybacks.

Key Risks

• Execution risk on Informatica integration & restructuring.
• Prolonged macro slowdown weighing on enterprise software budgets.
• AI/automation competition from MSFT, ORCL, and specialist SaaS vendors.
• Management discipline risk if they revert to large, dilutive acquisitions.
• Short-term optical GAAP EPS hit from amortization & restructuring spooking the market again.

None of these automatically kill the long-term thesis, but they can delay the rerating and increase volatility.

Conclusion

CRM is in the ugly middle phase of a transformation:

• Growth investors are leaving,
• Value investors are slowly entering,
• Fundamentals are better than the chart suggests.

What you’re really buying:

• A high-quality, entrenched SaaS platform,
• With the best gross margins in its peer group,
• A clear path to higher GAAP margins & EPS,
• And a stock priced as if none of that will ever happen.

Verdict: BUY (for patient capital).

Accumulate on weakness into US$218–212,

Aim for a multi-year rerating toward US$280–300+ once the margin story shows up in GAAP numbers.

Disclaimer

Gotrade is the trading name of Gotrade Securities Inc., registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.